Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.